HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank Lehmann-Horn Selected Research

Paralysis (Palsy)

7/2019Strength and muscle structure preserved during long-term therapy in a patient with hypokalemic periodic paralysis (Cav1.1-R1239G).
10/20167-T (35)Cl and (23)Na MR Imaging for Detection of Mutation-dependent Alterations in Muscular Edema and Fat Fraction with Sodium and Chloride Concentrations in Muscular Periodic Paralyses.
10/2016Successful treatment of periodic paralysis with coenzyme Q10: two case reports.
1/20167-T (35)Cl and (23)Na MR Imaging for Detection of Mutation-dependent Alterations in Muscular Edema and Fat Fraction with Sodium and Chloride Concentrations in Muscular Periodic Paralyses.
4/2014NaV1.4 mutations cause hypokalaemic periodic paralysis by disrupting IIIS4 movement during recovery.
12/2013Transient compartment-like syndrome and normokalaemic periodic paralysis due to a Ca(v)1.1 mutation.
4/2005Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence.
10/2003Impaired slow inactivation due to a polymorphism and substitutions of Ser-906 in the II-III loop of the human Nav1.4 channel.
4/2002Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank Lehmann-Horn Research Topics

Disease

10Hypokalemic Periodic Paralysis (Periodic Paralysis, Hypokalemic)
07/2019 - 04/2002
10Channelopathies
09/2017 - 01/2002
9Paralysis (Palsy)
07/2019 - 04/2002
5Myotonia
10/2020 - 04/2012
5Edema (Dropsy)
07/2019 - 12/2011
4Malignant Hyperthermia
01/2014 - 11/2002
3Myotonia Congenita (Thomsen Disease)
10/2020 - 08/2012
3Epilepsy (Aura)
10/2019 - 01/2005
3Contracture
01/2014 - 09/2005
2Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
01/2017 - 05/2012
2Muscle Weakness
11/2013 - 08/2006
2Muscle Cramp (Cramp)
04/2012 - 09/2005
2Myotonic Disorders (Paramyotonia Congenita)
04/2007 - 08/2006
1Intellectual Disability (Idiocy)
10/2019
1Deafness (Deaf Mutism)
10/2019
1Chronic Brain Damage
10/2019
1Nonsyndromic Deafness
10/2019
1Seizures (Absence Seizure)
10/2019
1Nervous System Diseases (Neurological Disorders)
10/2019
1Myoclonus (Nocturnal Myoclonus)
10/2019
1Potassium aggravated myotonia
09/2017
1Neoplasms (Cancer)
05/2014
1Myasthenia Gravis
11/2013
1Hypokalemia
11/2013
1Thymus Hyperplasia
11/2013
1Fatigue
12/2012
1Hyperkalemic Periodic Paralysis
07/2012
1Andersen Syndrome
02/2012
1Episodic Ataxia
10/2011
1Leukoencephalopathies
10/2011
1Central Core Myopathy (Central Core Disease)
04/2009
1Minicore Myopathy with External Ophthalmoplegia
04/2009
1Migraine Disorders (Migraine)
06/2008
1Hemolysis
06/2008
1Dyskinesias (Dyskinesia)
06/2008
1Hemolytic Anemia
06/2008
1Muscular Atrophy (Muscle Atrophy)
01/2008
1Pelvic Pain
01/2006
1Fibrosis (Cirrhosis)
01/2006
1Torticollis (Wryneck)
01/2006
1Hyperkalemia
09/2005
1Rhabdomyolysis
09/2005
1Fasciculation (Fasciculations)
09/2005
1Hyperthermia
09/2005

Drug/Important Bio-Agent (IBA)

10SodiumIBA
07/2019 - 08/2006
7PotassiumIBA
10/2020 - 11/2013
6Ion Channels (Ion Channel)IBA
10/2016 - 01/2002
5ChloridesIBA
10/2020 - 01/2016
5Proteins (Proteins, Gene)FDA Link
10/2019 - 01/2002
5Sodium Channels (Sodium Channel)IBA
04/2014 - 04/2002
4Calcium Channels (Calcium Channel)IBA
12/2013 - 04/2002
3Eplerenone (Inspra)FDA LinkGeneric
01/2017 - 05/2012
3Protons (Proton)IBA
07/2012 - 11/2002
2Chloride Channels (Chloride Channel)IBA
01/2020 - 08/2012
2CalciumIBA
04/2014 - 12/2013
2Caffeine (No Doz)FDA LinkGeneric
01/2014 - 09/2005
2CationsIBA
03/2009 - 06/2008
2Mexiletine (Mexitil)FDA LinkGeneric
08/2006 - 04/2005
1Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA
10/2020
19-anthroic acidIBA
01/2020
1Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA
01/2020
1paxillineIBA
01/2020
1Spironolactone (Aldactone)FDA LinkGeneric
07/2019
1DiureticsIBA
01/2017
1GlucocorticoidsIBA
01/2017
1coenzyme Q10 (CoQ10)IBA
10/2016
1Mineralocorticoid Receptor AntagonistsIBA
10/2016
1ChlorineIBA
01/2016
1Arginine (L-Arginine)FDA Link
04/2014
1Halothane (Fluothane)FDA Link
01/2014
1Cysteine (L-Cysteine)FDA Link
01/2014
1Thyroid HormonesIBA
11/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2013
1AutoantibodiesIBA
11/2013
1Adrenocorticotropic Hormone (ACTH)FDA Link
11/2013
1Hydrocortisone (Cortisol)FDA LinkGeneric
11/2013
1Keratin-5 (Keratin 5)IBA
11/2013
1LDL Receptors (LDL Receptor)IBA
11/2013
1Cholinergic ReceptorsIBA
11/2013
1CalpainIBA
12/2012
1Peptide Hydrolases (Proteases)FDA Link
12/2012
1HydrogenIBA
07/2012
1Lidocaine (Xylocaine)FDA LinkGeneric
04/2012
1Inwardly Rectifying Potassium Channels (Inward Rectifier Potassium Channels)IBA
02/2012
1trans-sodium crocetinate (crocetin)IBA
12/2011
1Lactic Acid (Lactate)FDA LinkGeneric
10/2011
1Aspartate-tRNA LigaseIBA
10/2011
1Acetazolamide (Diamox)FDA LinkGeneric
10/2011
1Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA
04/2009
1Glucose (Dextrose)FDA LinkGeneric
06/2008
1ElectrolytesIBA
06/2008
1Complement System Proteins (Complement)IBA
01/2006
1N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA
09/2005
1RNA (Ribonucleic Acid)IBA
08/2005
1AntibodiesIBA
08/2005

Therapy/Procedure

3Therapeutics
01/2020 - 08/2006
1Physical Therapy Modalities (Physical Therapy Technique)
07/2019
1General Anesthesia
01/2014
1Thymectomy
11/2013
1Aftercare (After-Treatment)
08/2006